CDK Inhibitors: From the Bench to Clinical Trials

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|11|3|279-290

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.3, 2010-03, pp. : 279-290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tirapazamine: From Bench to Clinical Trials

By  

Current Clinical Pharmacology, Vol. 1, Iss. 1, 2006-01 ,pp. : 71-79

Bentham Science Publishers

Access to resources Recommend Favorite

Gene Therapy for Parkinson's and Alzheimer's Diseases: from the Bench to Clinical Trials

By  

Current Pharmaceutical Design, Vol. 17, Iss. 31, 2011-10 ,pp. : 3434-3445

Bentham Science Publishers

Access to resources Recommend Favorite

Histone deacetylase inhibitors: from target to clinical trials

By Kelly William K   O’Connor Owen A   Marks Paul A  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 12, 2002-12 ,pp. : 1695-1713

Informa Healthcare

Access to resources Recommend Favorite

CDK inhibitors in clinical development for the treatment of cancer

By Fischer Peter M   Gianella-Borradori Athos  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 955-970

Informa Healthcare

Access to resources Recommend Favorite

Exceptional Matters: clinical research from bedside to bench

By Peters Keith  

Clinical Medicine, Vol. 4, Iss. 6, 2004-11 ,pp. : 551-566

Royal College Of Physicians

Access to resources Recommend Favorite